We're pleased to announce today is our Nasdaq listing day! We've begun trading under NAMS as we continue our work to bring obicetrapib, a transformative, clinically validated, oral therapy, to patients with cardiometabolic diseases. https://bit.ly/3VjBY3c #NasdaqListed
NewAmsterdam Pharma Corporation
Biotechnology
Aventura, Florida 7,100 followers
NewAmsterdam Pharma Corporation is a clinical-stage biopharma company creating therapies for cardiometabolic diseases.
About us
This page is intended for US audiences. Founded in 2019, NewAmsterdam Pharma Corporation is a late-stage clinical biopharmaceutical company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. The Company is investigating a selective cholesteryl ester transfer protein (CETP) inhibitor as an LDL-C lowering therapy for patients who cannot be treated optimally with currently available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy.
- Website
-
https://www.newamsterdampharma.com
External link for NewAmsterdam Pharma Corporation
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Aventura, Florida
- Type
- Public Company
- Founded
- 2019
Locations
-
Primary
Aventura, Florida, US
Employees at NewAmsterdam Pharma Corporation
Updates
-
Statins alone aren’t enough to get many people to their LDL-C goals. As Prof. Stephen Nicholls notes, we need additional lipid-lowering therapy options to help reduce the global burden of cardiovascular disease.
-
In a survey of nearly 1,200 patients presented at #ACC24, oral lipid-lowering therapies were “significantly more preferred to all injectable regimens.” We continue to advance our pipeline of investigational oral options for lowering LDL-C. https://bit.ly/3YkENFN
-
Understanding your family’s history with cholesterol, and the connections between lipids and cardiovascular disease, is immensely important, as the Gradney family’s story highlights. Read about their 8-year journey to an FH diagnosis. Family Heart Foundation https://bit.ly/4bZjn4e
-
We’re excited to announce the addition of two new members to our Board of Directors: Mark McKenna and Wouter Joustra. These appointments bring valuable expertise to our Board in pharmaceutical industry leadership and life sciences investments as we approach pivotal Phase 3 data readouts from multiple clinical trials. https://bit.ly/3y5nvSl We’d also like to thank Sander Slootweg, who is departing the Board, for his significant contributions and dedication.
-
“FH is much more common than we once thought...” -- Dr. Joshua Knowles Familial hypercholesteremia (FH) affects 1 in every 220 people across all ages and ethnic backgrounds. As you’ll hear in this American Heart Association podcast, that’s at least 1.3 million Americans and as few as 10% have been properly diagnosed. https://bit.ly/4f87bkA
-
Our team spent the weekend at the 56th Annual Scientific Meeting of the Japan Atherosclerosis Society, including hosting a lunch seminar led by Prof. John Kastelein and Prof. Stephen Nicholls exploring CETP as a therapeutic target for the clinical management of LDL-C.
-
We’re excited to announce patient enrollment is complete in our pivotal Phase 3 TANDEM clinical trial. https://bit.ly/4czF7F8 The study evaluates the fixed-dose combination of our lead investigational candidate, obicetrapib, plus ezetimibe in adults with heterozygous familial hypercholesterolemia, ASCVD, or multiple ASCVD risk factors whose LDL-C is not adequately controlled with maximally tolerated lipid-modifying therapies.
-
NewAmsterdam Pharma Corporation reposted this
Study results are expected for two closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs. #biotech #pharma
-
A recent JAMA Cardiology study found that higher Lp(a) was associated with increased cardiovascular risk regardless of hs-CRP levels. We are investigating the potential effects of CETP inhibition on Lp(a). https://bit.ly/3Ljp8ix